‹ ›
MYP_020204
← PREVIOUS NEXT → BACK
Basic Information
HP23-E6-IDL
Anticancer ▸ Cytotoxic anticancer activity ▸ Cytotoxic
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral fusion inhibition
Toxicity / Safety ▸ Cytotoxicity ▸ Cytotoxic
Venom / Toxin ▸ General toxin ▸ Cytotoxic
Standard
32 amino acids
C182H288N44O59S
Standard
Sequence
EMTWEEWEKKIEEYTKKIEEILKKSQNQQIDL
Physicochemical Analysis
4068.56 Da
4.73
-3.15
-3.34
-0.0984
-1.46
0.68
-0.29
68.53
73.12
0.0938
12490.00
12490.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
1742.10
-11.55
58.0
57.0
148.0
286.0
5.0
35.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0148726 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 NL4-3 D36G/V38A
PMID30901967 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30901967/
RECORD: Rec_0156038 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 NL4-3 (5 HP23-Resistant Strains,WT,E49K,E49K/N126K,D36G/E49K/N126K,L34S/D36G/E49K/E136G) | MT-2 cells
0.000699-0.004937 μM
IC50
Mammalian: 1 h; Yeast: 30 min; E. coli: >10 h
PaperA Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. | Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. | Molecules. 2019 Mar 21;24(6):1134. | DOI:10.3390/molecules24061134 | PMID:30901967 PMID30901967 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30901967/
RECORD: Rec_0180264 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral
inhibition of cell-cell fusion between H9/IIIB cells and MT-2 cells
0.00114 μM
IC50
PaperPubMed PMID: 30901967 PMID30901967 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30901967/
RECORD: Rec_0181689 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral
HIV-1 IIIB
PMID30901967 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30901967/
RECORD: Rec_0189738 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Fusion-inhibitory peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Fusion inhibition
HIV-1 NL4-3 D36G (6 T-20 resistant strains, WT,V38A,V38A/N42D,V38E/N42S,V38A/N42T,N42T/N43K) | MT-2 cells
0.000748-0.001543 μM
IC50
Mammalian: 1 h; Yeast: 30 min; E. coli: >10 h
PaperA Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. | Su S, Rasquinha G, Du L, Wang Q, Xu W, Li W, Lu L, Jiang S. | Molecules. 2019 Mar 21;24(6):1134. | DOI:10.3390/molecules24061134 | PMID:30901967 PMID30901967 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/30901967/
FIRST PREV 1 2 3 4 5 NEXT LAST
Showing 5 records on this page · Page 2 of 5